Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide's Effect on CGRP in Migraine
NCT05632133Phase 3Completed
- Sponsor
- Kafrelsheikh University
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lacosamide in migraine (2 arms), sponsored by Kafrelsheikh University. Primary endpoint: Serum Calcitonin Gene-Related Peptide Concentration at 3 months. Started Jun 2022; status: completed.
02
Drugs
lacosamide
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05632133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632133.